Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial
29 April 2017 (08:30 - 17:30)
Organised by:
Abstract
About the speaker
St. Michael's Hospital, Toronto (Canada)
8 More presentations in this session
Access the full session
The Event
Heart Failure 2017 - 4th World Congress on Acute Heart Failure
29 April 2017
08:30 CET
